ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pamvatamig

Also written as “MCLA-129” and “MCLA-129: 1500mg or 2000mg IV Q2W”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms, led by 2 companies.

Drug pagePamvatamig: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since May 31, 20215 company-led studies, 4 open or runningNext primary completion: Apr 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Betta Pharmaceuticalsits history only44 open or runningphase 2since May 31, 2021May 31, 2021Apr 2028phase 2 · NCT06885840
Genmab10 open or runningphase 2since Apr 9, 2021Apr 9, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Genmab only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Apr 9, 2021First study: phase 2 study in Stomach NeoplasmsFirst studyNCT04868877 · 194 enrolled · United States, Belgium, France and more
  2. Aug 6, 2023Named pamvatamigINNProposed as its International Nonproprietary Name in WHO's List 129 · before, MCLA-129
  3. Oct 26, 2026Phase 2 study terminatedStudy stoppedNCT04868877 · “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefi…”
  4. Oct 26, 2026Primary completion moved from 2026-03 to 2026-10-01Date moved laterphase 2 · +7 months · NCT04868877

TargetBeta

EGFR →MET →read by rule
“A human bispecific immunoglobulin G1 (IgG1) antibody targeting the tumor-associated antigens (TAAs) epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (HGFR; c-Met), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
amivantamabruleJohnson & Johnsonphase 316
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
HS-20117Hansoh Pharmaceutical Groupphase 33
TQB2922Sino Biopharmaceuticalphase 25
TQB6411Sino Biopharmaceuticalphase 23
Anti-EGFR/Anti-c-Met Bispecific Antibody-drug Conjugate VBC101ruleVelaVigo Caymanphase 21
Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412ruletavotek-biotherapeuticsphase 12
HS-20122Hansoh Pharmaceutical Groupphase 12
Anti-EGFR/c-Met/c-Met-Topoisomerase-1 Inhibitor Trispecific Antibody-drug Conjugate BG-C0902ruleBeOne Medicinesphase 11
Anti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446Johnson & Johnsonphase 11
HLX48Fosun Pharmaphase 11

Studies

The one study Genmab leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04868877Stomach Neoplasms · United States, Belgium, France and more2TerminatedOct 1, 2026194

How it is read

Names in the registry

  • “MCLA-129”, 4 entries
  • “MCLA-129: 1500mg or 2000mg IV Q2W”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.